We are live on ! Find out more
CS

Credit Suisse Portfolio holdings

AUM $104B
1-Year Est. Return 34.76%
This Fund
S&P 500
This Quarter Est. Return
+8.7%
1 Year Est. Return
+34.76%
3 Year Est. Return
+49.35%
5 Year Est. Return
+181.01%
10 Year Est. Return
+395.52%
AUM
$189B
AUM Growth
-$6.65B
Cap. Flow
-$21B
Cap. Flow %
-11.12%
Top 10 Hldgs %
16.9%
Holding
4,784
New
635
Increased
1,494
Reduced
2,137
Closed
388

Sector Composition

Rank Sector Weight
1 Technology 14.66%
2 Healthcare 11.06%
3 Financials 8.17%
4 Consumer Discretionary 8.09%
5 Communication Services 6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MSBI icon
3901
Midland States Bancorp
MSBI
$717M
$349K ﹤0.01%
13,324
-3,035
-19% -$84.3K
ACEL icon
3902
Accel Entertainment
ACEL
$990M
$348K ﹤0.01%
29,517
-472
-2% -$5.86K
EPIX
3903
DELISTED
ESSA Pharma
EPIX
$348K ﹤0.01%
+12,226
New +$355K
PEBO icon
3904
Peoples Bancorp
PEBO
$1.5B
$348K ﹤0.01%
11,760
-4,638
-28% -$151K
PTRA
3905
DELISTED
Proterra Inc. Common Stock
PTRA
$348K ﹤0.01%
+20,326
New +$342K
GIIX
3906
DELISTED
Gores Holdings VIII, Inc. Class A Common Stock
GIIX
$347K ﹤0.01%
+35,000
New +$348K
XENE icon
3907
Xenon Pharmaceuticals
XENE
$6.19B
$346K ﹤0.01%
18,617
-5,474
-23% -$101K
PTVE
3908
DELISTED
Pactiv Evergreen Inc. Common stock
PTVE
$346K ﹤0.01%
+23,016
New +$345K
TCRT icon
3909
Alaunos Therapeutics
TCRT
$4.64M
$345K ﹤0.01%
870
-193
-18% -$90.1K
UVE icon
3910
Universal Insurance Holdings
UVE
$1.23B
$345K ﹤0.01%
25,032
-2,876
-10% -$40.4K
ARKO icon
3911
ARKO Corp
ARKO
$840M
$344K ﹤0.01%
37,525
+3,568
+11% +$36.3K
PGC icon
3912
Peapack-Gladstone Financial
PGC
$827M
$342K ﹤0.01%
11,034
-6,469
-37% -$209K
NWLI
3913
DELISTED
National Western Life Group, Inc. Class A
NWLI
$342K ﹤0.01%
1,527
-493
-24% -$118K
IHC
3914
DELISTED
Independence Holding Company
IHC
$342K ﹤0.01%
7,320
+1,017
+16% +$45.1K
IEO icon
3915
iShares US Oil & Gas Exploration & Production ETF
IEO
$560M
$341K ﹤0.01%
5,953
-11,558
-66% -$612K
IYM icon
3916
iShares US Basic Materials ETF
IYM
$1.21B
$341K ﹤0.01%
2,612
-2,434
-48% -$325K
CMRX
3917
DELISTED
Chimerix, Inc.
CMRX
$341K ﹤0.01%
+42,709
New +$355K
INVZ icon
3918
Innoviz Technologies
INVZ
$92.4M
0
NWS icon
3919
News Corp Class B
NWS
$17.7B
$340K ﹤0.01%
13,976
-2,214
-14% -$54.7K
ENIA
3920
DELISTED
Enel Amricas S.A. American Depositary Shares (Each representing 50 shares of Common Stock)
ENIA
$340K ﹤0.01%
46,996
+5,117
+12% +$37.6K
EBF icon
3921
Ennis
EBF
$565M
$337K ﹤0.01%
15,843
-6,830
-30% -$144K
TBRG
3922
DELISTED
TruBridge
TBRG
$337K ﹤0.01%
10,159
+145
+1% +$4.6K
DCO icon
3923
Ducommun
DCO
$2.89B
$336K ﹤0.01%
6,267
-68
-1% -$3.86K
KBAL
3924
DELISTED
Kimball International
KBAL
$335K ﹤0.01%
25,510
-18,766
-42% -$256K
LILA icon
3925
Liberty Latin America Class A
LILA
$1.69B
$334K ﹤0.01%
35,639
-5,914
-14% -$56.1K

Similar funds

Credit Suisse's Q2 2021 Portfolio in Review

As of Q2 2021, Credit Suisse held 4,784 positions worth $189B, down 3.4% from $195B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Credit Suisse withdrew a net $21B in Q2 2021, closing 388 positions and reducing 2,137 holdings. Its most notable exit was INPHI CORPORATION, an estimated $356M position sold in full.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Credit Suisse opened a new position in Recursion Pharmaceuticals worth $52.9M.

  • Credit Suisse's largest Q2 2021 buy was Recursion Pharmaceuticals: 1,449,585 shares worth $52.9M.
  • Credit Suisse added most to iShares Core S&P 500 ETF in Q2 2021, an estimated $826M increase.
  • Credit Suisse's biggest Q2 2021 reduction was Alibaba, cutting an estimated $1.27B.
  • Credit Suisse fully exited INPHI CORPORATION in Q2 2021, selling an estimated $356M.
  • Credit Suisse's ten largest holdings make up 17% of its $189B portfolio in Q2 2021.
  • Credit Suisse opened 635 new positions and closed 388 in Q2 2021.
  • Credit Suisse's portfolio value fell 3.4% quarter-over-quarter to $189B.

Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.